Market Price

141.43 

-0.60 -0.4%

as of Dec 10 '17 23:59

52 Week Range:

91.62 149.30


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, and internationally. It operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of bleeding disorders, including hemophilia and von Willebrand disease, primary and secondary immunodeficiency’s, hereditary angioedema, neurological disorders, and inherited respiratory diseases. Its products are also used to prevent haemolytic diseases in newborns and infections in solid organ transplant recipients, as well as specific infections; and for urgent warfarin reversal in patients with acute major bleeding, as well as victims of trauma, shocks, and burns. In addition, this segment operates approximately 180 human blood plasma collection centers. Further, it conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and offers influenza vaccines. It also provides in-licensed vaccines and specialty pharmaceuticals; manufactures and markets diagnostics for immunohematology laboratories; and supplies a range of products, including antivenoms and Q fever vaccines. The company was founded in 1916 and is headquartered in Parkville, Australia.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jun '07 Jun '08 Jun '09 Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17
Equity (BVPS) 3.91
5.10
9.12
7.67
6.94
7.19
7.03
6.83
7.22
7.83
7.63
growth rate 30.4% 78.8% -15.9% -9.5% 3.6% -2.2% -2.8% 5.7% 8.5% -2.6%
Earnings BIT 774.06
952.02
1,370.00
1,380.00
1,200.00
1,220.00
1,480.00
1,637.00
1,758.00
1,438.00
1,769.00
growth rate 23.0% 43.9% 0.7% -13.0% 1.7% 21.3% 10.6% 7.4% -18.2% 23.0%
Avg.PE 29.76
28.17
16.78
17.61
19.05
20.88
23.47
23.31
31.97
36.98
43.60
growth rate -5.3% -40.4% 5.0% 8.2% 9.6% 12.4% -0.7% 37.2% 15.7% 17.9%
ROA 12.86
15.78
19.00
16.10
17.45
18.05
21.39
21.17
23.94
18.07
15.77
growth rate 22.7% 20.4% -15.3% 8.4% 3.4% 18.5% -1.0% 13.1% -24.5% -12.7%
ROE 25.33
27.66
27.72
21.76
23.94
27.79
39.32
42.05
51.80
47.57
45.94
growth rate 9.2% 0.2% -21.5% 10.0% 16.1% 41.5% 6.9% 23.2% -8.2% -3.4%
ROIC 17.32
20.36
23.03
18.98
21.21
22.39
27.30
27.31
31.11
24.60
21.70
growth rate 17.6% 13.1% -17.6% 11.8% 5.6% 21.9% 0.0% 13.9% -20.9% -11.8%
Cur. Ratio 2.79
3.12
4.04
4.24
2.92
3.62
3.60
3.79
3.57
2.78
2.84
growth rate 11.8% 29.5% 5.0% -31.1% 24.0% -0.6% 5.3% -5.8% -22.1% 2.2%
Quick Ratio 1.34
1.66
2.76
2.36
1.35
2.03
1.74
1.80
1.62
1.16
1.21
growth rate 23.9% 66.3% -14.5% -42.8% 50.4% -14.3% 3.5% -10.0% -28.4% 4.3%
Leverage 1.85
1.67
1.35
1.35
1.39
1.70
1.99
1.99
2.33
2.95
2.88
growth rate -9.7% -19.2% 0.0% 3.0% 22.3% 17.1% 0.0% 17.1% 26.6% -2.4%
Balance Sheet Jun '07 Jun '08 Jun '09 Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17
Acct.Receivable 570.12
10.20
7.60
779.00
761.00
822.00
915.00
979.00
1,044.00
1,114.00
growth rate -98.2% -25.5% 10,150.0% -2.3% 8.0% 11.3% 7.0% 6.6% 6.7%
Acct.Payable 245.00
221.00
261.00
214.00
258.00
304.00
399.00
growth rate -9.8% 18.1% -18.0% 20.6% 17.8% 31.3%
Cur.Assets 2,610.60
4,949.00
3,339.20
2,762.00
3,445.00
3,259.00
3,208.00
3,339.00
3,818.00
4,602.00
growth rate 89.6% -32.5% -17.3% 24.7% -5.4% -1.6% 4.1% 14.4% 20.5%
Total Assets 4,695.00
7,366.80
5,711.00
5,068.00
5,901.00
5,974.00
6,278.00
6,401.00
7,563.00
9,123.00
growth rate 56.9% -22.5% -11.3% 16.4% 1.2% 5.1% 2.0% 18.2% 20.6%
Cash 673.43
2,528.10
1,001.10
479.00
1,171.00
762.00
609.00
557.00
557.00
845.00
growth rate 275.4% -60.4% -52.2% 144.5% -34.9% -20.1% -8.5% 0.0% 51.7%
Inventory 1,147.57
1,522.00
1,454.60
1,456.00
1,483.00
1,639.00
1,645.00
1,756.00
2,152.00
2,576.00
growth rate 32.6% -4.4% 0.1% 1.9% 10.5% 0.4% 6.8% 22.6% 19.7%
Cur.Liabilities 836.00
1,225.70
786.90
946.00
950.00
907.00
845.00
936.00
1,374.00
1,618.00
growth rate 46.6% -35.8% 20.2% 0.4% -4.5% -6.8% 10.8% 46.8% 17.8%
Liabilities 1,888.80
1,903.90
1,495.90
1,424.00
2,425.00
2,956.00
3,116.00
3,654.00
4,996.00
5,959.00
growth rate 0.8% -21.4% -4.8% 70.3% 21.9% 5.4% 17.3% 36.7% 19.3%
LT Debt 692.27
790.31
385.40
436.20
163.00
1,096.00
1,650.00
1,859.00
2,255.00
3,059.00
3,830.00
growth rate 14.2% -51.2% 13.2% -62.6% 572.4% 50.6% 12.7% 21.3% 35.7% 25.2%
Equity 2,268.85
2,806.10
5,462.90
4,215.20
3,644.40
3,428.30
3,241.80
3,356.70
growth rate 23.7% 94.7% -22.8% -13.5% -5.9% -5.4% 3.5%
Common Shares 551.00
553.00
598.00
569.00
542.00
520.00
500.00
486.00
472.00
463.00
456.00
growth rate 0.4% 8.1% -4.9% -4.8% -4.1% -3.9% -2.8% -2.9% -1.9% -1.5%
Cash Flow Statement Jun '07 Jun '08 Jun '09 Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17
Capital Expenditures 284.79
219.34
284.20
243.60
199.00
309.00
433.00
354.00
348.00
495.00
689.00
growth rate -23.0% 29.6% -14.3% -18.3% 55.3% 40.1% -18.2% -1.7% 42.2% 39.2%
Cash Dividends 162.53
203.89
319.50
429.50
435.90
422.10
538.40
553.60
growth rate 25.5% 56.7% 34.4% 1.5% -3.2% 27.6% 2.8%
Cash From OA 480.84
617.91
1,024.80
1,168.50
1,018.00
1,206.00
1,312.00
1,361.00
1,364.00
1,179.00
1,247.00
growth rate 28.5% 65.9% 14.0% -12.9% 18.5% 8.8% 3.7% 0.2% -13.6% 5.8%
FCF per Share 0.36
0.85
1.18
1.53
1.49
1.49
1.63
1.86
2.10
2.62
1.78
growth rate 136.1% 38.8% 29.7% -2.6% 0.0% 9.4% 14.1% 12.9% 24.8% -32.1%
FCF -294.00
471.00
707.00
872.00
806.00
849.00
929.00
1,018.00
1,237.00
825.00
502.00
growth rate 100.0% 50.1% 23.3% -7.6% 5.3% 9.4% 9.6% 21.5% -33.3% -39.2%
Income Statement Jun '07 Jun '08 Jun '09 Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17
Sales 2,500.00
3,556.70
4,640.30
4,473.90
4,188.00
4,616.00
4,950.00
5,335.00
5,459.00
6,115.00
6,923.00
growth rate 42.3% 30.5% -3.6% -6.4% 10.2% 7.2% 7.8% 2.3% 12.0% 13.2%
Op.Income 755.10
1,032.50
1,244.60
941.00
1,024.00
1,480.00
1,637.00
1,758.00
1,438.00
1,769.00
growth rate 36.7% 20.5% -24.4% 8.8% 44.5% 10.6% 7.4% -18.2% 23.0%
IBT 853.48
1,369.70
1,379.50
1,198.10
1,216.80
1,582.10
1,703.10
growth rate 60.5% 0.7% -13.2% 1.6% 30.0% 7.7%
Net Income 701.80
1,145.90
1,052.90
941.00
1,024.00
1,211.00
1,307.00
1,379.00
1,242.00
1,337.00
growth rate 63.3% -8.1% -10.6% 8.8% 18.3% 7.9% 5.5% -9.9% 7.7%
EPS 0.97
1.27
1.92
1.85
1.73
1.89
2.62
2.86
3.81
3.61
3.81
growth rate 30.9% 51.2% -3.7% -6.5% 9.3% 38.6% 9.2% 33.2% -5.3% 5.5%
Gross Profit 1,434.85
1,628.00
2,240.60
2,289.10
2,059.00
2,227.00
2,559.00
2,731.00
2,853.00
3,063.00
3,596.00
growth rate 13.5% 37.6% 2.2% -10.1% 8.2% 14.9% 6.7% 4.5% 7.4% 17.4%
R&D 311.60
316.70
325.10
355.00
460.20
495.10
growth rate 1.6% 2.7% 9.2% 29.6% 7.6%

Quarterly Statements

Item Name Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Earnings BIT 346.00
547.00
547.00
337.00
337.00
growth rate 58.1% 0.0% -38.4% 0.0%
Balance Sheet Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Acct.Receivable 1,044.00
1,209.00
1,209.00
1,114.00
1,114.00
growth rate 15.8% 0.0% -7.9% 0.0%
Acct.Payable 304.00
976.00
976.00
399.00
399.00
growth rate 221.1% 0.0% -59.1% 0.0%
Cur.Assets 3,818.00
4,224.00
4,224.00
4,602.00
4,602.00
growth rate 10.6% 0.0% 9.0% 0.0%
Total Assets 7,563.00
8,130.00
8,130.00
9,123.00
9,123.00
growth rate 7.5% 0.0% 12.2% 0.0%
Cash 557.00
885.00
885.00
845.00
845.00
growth rate 58.9% 0.0% -4.5% 0.0%
Inventory 2,152.00
2,125.00
2,125.00
2,576.00
2,576.00
growth rate -1.3% 0.0% 21.2% 0.0%
Cur.Liabilities 1,374.00
1,257.00
1,257.00
1,618.00
1,618.00
growth rate -8.5% 0.0% 28.7% 0.0%
Liabilities 4,996.00
5,223.00
5,223.00
5,959.00
5,959.00
growth rate 4.5% 0.0% 14.1% 0.0%
LT Debt 3,059.00
3,508.00
3,508.00
3,830.00
3,830.00
growth rate 14.7% 0.0% 9.2% 0.0%
Equity
growth rate
Common Shares
growth rate
Cash Flow Statement Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Capital Expenditures 139.00
140.00
140.00
204.00
204.00
growth rate 0.7% 0.0% 45.7% 0.0%
Cash Dividends
growth rate
Cash From OA 237.00
332.00
332.00
291.00
291.00
growth rate 40.1% 0.0% -12.4% 0.0%
FCF 98.00
192.00
192.00
87.00
87.00
growth rate 95.9% 0.0% -54.7% 0.0%
Income Statement Jun '16 Sep '16 Dec '16 Mar '17 Jun '17
Sales 1,427.00
1,838.00
1,838.00
1,623.00
1,623.00
growth rate 28.8% 0.0% -11.7% 0.0%
Op.Income 346.00
547.00
547.00
337.00
337.00
growth rate 58.1% 0.0% -38.4% 0.0%
Net Income 262.00
403.00
403.00
266.00
266.00
growth rate 53.8% 0.0% -34.0% 0.0%
Gross Profit 719.00
951.00
951.00
847.00
847.00
growth rate 32.3% 0.0% -10.9% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (38.50)

YOY Growth Grade:

D (44.65)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 48.51 48.25 35.28
EPS / Growth 3.1% 2.93 14.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 0.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.7% 1.9% 1.9%
Future PE 1.30 29.17 29.17
Future EPS 3.13 3.52 3.52
Value Price
MOS %
1.00
-99.3%
25.41
-82.0%
25.41
-82.0%
MOS Price 0.50 12.71 12.71
IRT 41.87 34.28 34.28

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.

Risk / Reward Ratios

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.